JP2016527006A - 骨成長を促進するための方法、システム、及び組成物 - Google Patents

骨成長を促進するための方法、システム、及び組成物 Download PDF

Info

Publication number
JP2016527006A
JP2016527006A JP2016527117A JP2016527117A JP2016527006A JP 2016527006 A JP2016527006 A JP 2016527006A JP 2016527117 A JP2016527117 A JP 2016527117A JP 2016527117 A JP2016527117 A JP 2016527117A JP 2016527006 A JP2016527006 A JP 2016527006A
Authority
JP
Japan
Prior art keywords
hydroxy
methyl
oxopyrrolidin
difluoro
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016527117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527006A5 (enExample
Inventor
バーレット，スティーヴン・ダグラス
コロンボ，ジョセフ・マイケル
ジャーメイン，ブラッドリー・デーヴィッド
コルニロフ，アンドリー
クレイマー，ジェームズ・バーナード
ウジーブロ，アダム
エンドレス，グレゴリー・ウィリアム
シスケ，フレッド・ローレンス
オーウェン，トーマス・アレン
オマリー，ジェームズ・ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cayman Chemical Co Inc
Original Assignee
Cayman Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Co Inc filed Critical Cayman Chemical Co Inc
Publication of JP2016527006A publication Critical patent/JP2016527006A/ja
Publication of JP2016527006A5 publication Critical patent/JP2016527006A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
JP2016527117A 2013-07-19 2014-07-18 骨成長を促進するための方法、システム、及び組成物 Pending JP2016527006A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361856370P 2013-07-19 2013-07-19
US61/856,370 2013-07-19
US201461928843P 2014-01-17 2014-01-17
US61/928,843 2014-01-17
PCT/US2014/047138 WO2015009991A2 (en) 2013-07-19 2014-07-18 Methods, systems, and compositions for promoting bone growth

Publications (2)

Publication Number Publication Date
JP2016527006A true JP2016527006A (ja) 2016-09-08
JP2016527006A5 JP2016527006A5 (enExample) 2017-08-31

Family

ID=51352759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527117A Pending JP2016527006A (ja) 2013-07-19 2014-07-18 骨成長を促進するための方法、システム、及び組成物

Country Status (9)

Country Link
US (1) US10729810B2 (enExample)
EP (1) EP3021879A2 (enExample)
JP (1) JP2016527006A (enExample)
KR (1) KR20160048054A (enExample)
CN (1) CN105392505A (enExample)
AU (1) AU2014290512A1 (enExample)
CA (1) CA2910398A1 (enExample)
PH (1) PH12015502854A1 (enExample)
WO (1) WO2015009991A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500157A (ja) * 2018-09-14 2022-01-04 オーソセル・リミテッド 人工骨膜

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
JP2017525407A (ja) * 2014-06-20 2017-09-07 株式会社スリー・ディー・マトリックス 歯の骨間隙を充填するための材料および方法
US9657052B2 (en) 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols
WO2016196925A1 (en) * 2015-06-04 2016-12-08 The Regents Of The University Of California Composition for bone and methods of making and using the same
CN105012995B (zh) * 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
HU231033B1 (hu) 2016-03-22 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására
CN105816919B (zh) * 2016-05-23 2019-06-11 烟台正海生物科技股份有限公司 一种含有天然纳米羟基磷灰石的复合材料及其制备方法
EP3526242A1 (en) * 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
CN108822090B (zh) * 2018-08-17 2020-11-17 杭州乐敦科技有限公司 一种他汀类药物中间体的制备方法
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
WO2020163290A1 (en) * 2019-02-04 2020-08-13 Emory University Sclerostin inhibitors that promote bone morphogenetic protein expression
CN110590351B (zh) * 2019-08-23 2021-05-25 中国科学院上海硅酸盐研究所 一种黑色生物活性陶瓷粉体及其应用
CN114014647B (zh) * 2021-10-21 2022-12-16 华南理工大学 一种硅酸锌复合磷酸三钙陶瓷支架及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137977A (ja) * 2001-07-23 2009-06-25 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
JP2010273847A (ja) * 2009-05-28 2010-12-09 Tokyo Institute Of Technology 高密度多孔質複合体
US20110237552A1 (en) * 2008-09-11 2011-09-29 Technische Universitaet Dresden Composite Material Consisting of a Collagen Matrix Mineralised with Silicate and Calcium Phosphate Phases, Method for the Production and Use Thereof
JP2012523853A (ja) * 2008-04-15 2012-10-11 エテックス コーポレーション リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ）

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
JP3388867B2 (ja) 1994-03-31 2003-03-24 株式会社東芝 宛名領域検出装置および宛名領域検出方法
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
ZA984040B (en) 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
WO2001046140A1 (en) 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
SI1339678T1 (sl) * 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
AU2002328338C1 (en) 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
AU2002328855B2 (en) 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
US7410991B2 (en) 2001-10-23 2008-08-12 Laboratoires Serono S.A. Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
AU2002346562A1 (en) 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
CA2466751A1 (en) 2001-12-03 2003-06-12 Merck And Co., Inc. Ep4 receptor agonist, compositions and methods thereof
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1490055A1 (en) 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
ATE336247T1 (de) 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
JP2006505572A (ja) 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
EP1586564B1 (en) 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
WO2004078103A2 (en) * 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
CA2549935A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JPWO2006016695A1 (ja) 2004-08-10 2008-05-01 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
EP1782830A4 (en) 2004-08-10 2009-07-29 Ono Pharmaceutical Co PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
US20060039949A1 (en) 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060057184A1 (en) 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US7621963B2 (en) * 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
WO2006130455A2 (en) 2005-05-27 2006-12-07 Royer Biomedical, Inc. Bioresorbable polymer matrices and methods of making and using the same
CA2619469C (en) 2005-09-09 2015-03-03 Wright Medical Technology, Inc. Composite bone graft cement comprising calcium sulfate dihydrate and brushite
KR20060013354A (ko) 2005-12-09 2006-02-09 (주)코리아 본 뱅크 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
EP2215084B1 (en) 2007-10-23 2016-09-28 Allergan, Inc. Therapeutic substituted lactams
US20090112332A1 (en) 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
US8685432B2 (en) 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
US20100021524A1 (en) 2008-07-22 2010-01-28 Osteogenex Inc. Pimethixene derivatives for promoting bone growth
WO2010025135A2 (en) 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
WO2011003058A1 (en) 2009-07-03 2011-01-06 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
JP5847830B2 (ja) 2010-11-10 2016-01-27 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬として有用なラクタム誘導体
AU2011329054B2 (en) * 2010-11-15 2015-05-28 Zimmer Orthobiologics, Inc. Bone void fillers
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
BR112014002377A2 (pt) 2011-08-02 2017-02-21 Ono Pharmaceutical Co agente intensificador da função diastólica do ventrículo esquerdo
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
BR112015023080A2 (pt) 2013-03-15 2017-07-18 Cayman Chemical Co Inc composto, composição farmacêutica, e, método para tratamento de doenças

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137977A (ja) * 2001-07-23 2009-06-25 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
JP2012523853A (ja) * 2008-04-15 2012-10-11 エテックス コーポレーション リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ）
US20110237552A1 (en) * 2008-09-11 2011-09-29 Technische Universitaet Dresden Composite Material Consisting of a Collagen Matrix Mineralised with Silicate and Calcium Phosphate Phases, Method for the Production and Use Thereof
JP2010273847A (ja) * 2009-05-28 2010-12-09 Tokyo Institute Of Technology 高密度多孔質複合体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BONE, 2004, VOL.34, PP.940-948, JPN6019001410, ISSN: 0004099480 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500157A (ja) * 2018-09-14 2022-01-04 オーソセル・リミテッド 人工骨膜
JP2024037985A (ja) * 2018-09-14 2024-03-19 オーソセル・リミテッド 人工骨膜

Also Published As

Publication number Publication date
WO2015009991A3 (en) 2015-07-16
US20160158413A1 (en) 2016-06-09
PH12015502854A1 (en) 2016-03-28
AU2014290512A1 (en) 2015-11-12
CN105392505A (zh) 2016-03-09
KR20160048054A (ko) 2016-05-03
US10729810B2 (en) 2020-08-04
WO2015009991A8 (en) 2015-12-17
WO2015009991A2 (en) 2015-01-22
AU2014290512A8 (en) 2016-06-16
CA2910398A1 (en) 2015-01-22
EP3021879A2 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
US10729810B2 (en) Methods, systems, and compositions for promoting bone growth
JP6766008B2 (ja) Ｅｐ４介在性骨関連疾患及び病態用ジフルオロラクタム組成物
EP2989098B1 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144610A1 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
HK1239518B (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1205937B (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1237785A1 (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
HK1206016B (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
HK1222170B (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190821